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Study objective: To describe patterns of excess mortality among patients with diabetes in three ethnic
groups.
Design: A linkage study of national hospital discharge records to death records.
Setting: New Zealand.
Participants: The study included 74 847 patients (11 268 Ma¯ori, 5730 Pacific, and 57 849 non-Ma¯ori/
non-Pacific) aged over 25 years with a hospital discharge diagnosis of diabetes between 1988 and 2001.
By the end of 2001, 29 295 (39%) of the cohort had died. Based on the underlying cause of death,
standardised mortality ratios (SMRs) (95% confidence intervals) were calculated for each ethnic group and
sex.
Main results: Comparing the mortality patterns of patients with diabetes to the general population of the
same ethnic group, adjusting for age and calendar period, all cause SMRs were higher for Ma¯ori women
and men: 3.80 (95% CI: 3.64 to 3.97) and 3.44 (95%CI: 3.30 to 3.58) than for Pacific (men: 2.41
(95%CI: 2.21 to 2.61); women: 2.23 (95%CI: 2.06 to 2.41)) and non-Ma¯ori/non-Pacific (men: 2.98
(95%CI: 2.93 to 3.04); women: 2.99 (95%CI: 2.93 to 3.04)) people. SMRs were significantly raised for
several causes of death, including cardiovascular disease and many site specific cancers.
Conclusions: The pattern of excess mortality among Ma¯ori with diabetes may relate to severity of disease.
This needs further investigation, as the excess mortality may be amenable to intervention.
M
ortality rates among people with type 2 diabetes are
higher than the general population. Estimates of the
magnitude of this excess mortality vary widely, and
although the differences are partially dependent on the
sources of the diabetes cases, such selection factors do not
seem to explain all of the reported differences in mortality.
Studies that identify diabetes patients through primary and
secondary care sources show slightly increased (25% to 50%)
standardised mortality ratios (SMR), although other popula-
tion based studies report SMRs or relative risks (RR) of about
twice that of the general population.1–3 Studies based on
patients with diabetes identified through hospital records
report higher SMRs,4 presumably because of the selective
inclusion of more severe cases of diabetes or patients with
comorbidities. Basing diagnosis on insulin use in type 2
diabetes also results in high all cause SMRs.5
Most previous reports examine broad categories of causes
of death, and there is general consensus that excess mortality
is evident for cardiovascular and renal disease.1 6 7 Cancer
mortality may also be increased,4 8 although not all studies
have found this1 6 7 and some studies have reported lower
SMRs for cancer mortality in patients with diabetes.9 There
are few reports that investigate site specific cancer mortality
in patients with diabetes.
The prevalence of diabetes in New Zealand differs by
ethnicity. A national survey of self reported doctor diagnosed
diabetes found lowest rates in New Zealand Europeans (2.5%
in women and 3.1% in men), and higher rates in Ma¯ori (9.8%
in women and 8.0% in men) and Pacific people (8.2% in
women and 6.8% in men).10 These differing rates across
ethnic groups are only partly explained by differing levels of
obesity.11 The aim of this study was to describe cause specific
mortality among patients admitted to a public hospital in
New Zealand, and to investigate whether these patterns
differed by ethnicity.
METHODS
The study entailed linkage between electronic hospital
discharge data and mortality data. Patients included in the
study were New Zealand residents who were discharged from
a public hospital with a code for diabetes mellitus, as
recorded on the National Minimum Dataset (NMDS)
between 1988 and 2001 and were aged 25 or over at the
time of discharge. Note that the included patients may or
may not have been diagnosed with diabetes before admis-
sion, but all had been diagnosed with diabetes at the time of
discharge. The International Classification of Disease (ICD-9)
codes used to define diabetes mellitus were 2500 to 2509.
People were identified using the National Health Index (NHI)
identifier, a number assigned to each person using health and
disability support services. For people with multiple diabetes
discharges, the first admission during the period 1988 to 2001
was used.
Ethnicity was assigned using the recorded ethnicity in the
NHI database, prioritised using the Ma¯ori, Pacific, non-
Ma¯ori/non-Pacific groups.12 The prioritised system minimises
the possibility of undercounting Ma¯ori and Pacific people.
The non-Ma¯ori/non-Pacific group is predominantly of
European origin, although does include a significant propor-
tion (about 7%) of Asians.
The cohort of patients with a discharge summary including
diabetes was linked to the national death registration data
held by the New Zealand Health Information Service
Abbreviations: SMR, standardised mortality ratio; RR, relative risk; CI,
confidence interval; NMDS, National Minimum Dataset
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(NZHIS). Follow up was from the date of the diabetes
admission until the earlier of either date of death or 31
December 2001, the date for which cause of death data were
available at the time of linkage. The underlying cause of
death was used for all analyses.
Statistical methods
SMRs were calculated by comparing the mortality rate
among patients with diabetes to the sex and ethnic specific
mortality rates of the New Zealand population. The rates used
for comparison were split by five year age bands and two year
calendar periods. Analysis was performed using the PC life
table analysis system.13 All reported p values are two sided.
RESULTS
Between February 1988 and December 2001, 76 684 people
were discharged from hospital with a code for type 2 diabetes
on their discharge summary (see above for clarification). The
following exclusions were made: not New Zealand residents
(n=1664, 2.2%), unknown sex (n=3, ,0.1%), apparently
died before diabetes diagnosis (n=11, ,0.1%), and missing
date of death (n=159, 0.2%). All analyses are based on
74 847 people (37 118 women and 37 729 men). These
people were followed up for a maximum of 13 years. By the
end of 2001, 29 295 (39.1%) cohort members had died.
Table 1 shows the characteristics of the study participants.
The median age at index discharge was about 13 years lower
for Ma¯ori and Pacific people compared with non-Maori/non-
Pacific people. The gap in median age at death between the
ethnic groups was a correspondingly wide, although Pacific
people, who were, on average, slightly younger than Ma¯ori at
index diagnosis, were older at death than Ma¯ori.
The all cause SMR for all patients combined was 3.02 (95%
confidence intervals (CI): 2.99 to 3.06). Significantly raised
SMRs were found for all major causes of death, including all
cancers combined (2.40, 95% CI: 2.34 to 2.47), diseases of the
circulatory (2.82, 95% CI: 2.77 to 2.87), respiratory (1.97, 95%
CI: 1.89 to 2.06), digestive (3.05, 95% CI: 2.85 to 3.26), and
genitourinary (3.31, 95% CI: 3.04 to 3.60) systems, as well as
external causes (1.99, 95% CI: 1.81 to 2.19). Site specific
cancer analyses showed that the sites at which diabetic
patients were most at risk, with an SMR exceeding 3.0, were
liver, gallbladder, pancreas, oro-pharynx, brain and nervous
system, and non-thyroid endocrine glands. However, sig-
nificantly raised SMRs (p,0.01) were evident for almost all
sites, including important sites of non-smoking related
Table 1 Description of all patients aged 25 years or more discharged from New Zealand public hospital with diabetes, 1988
to 2001
Women Men
number median range p value number median range p value *
Age at diabetes discharge
Ma¯ori 5654 58.0 25.0 to 95.5 ,0.001 5614 57.7 25.2 to 93.9 ,0.001
Pacific 3220 57.7 25.0 to 99.3 ,0.001 2510 57.5 25.2 to 97.1 ,0.001
Non-Ma¯ori/non-Pacific 28244 72.1 25.0 to 105.9 29605 69.3 25.0 to 102.9
Age at death
Ma¯ori 2003 66.3 29.1 to 96.7 ,0.001 2220 64.5 25.3 to 95.4 ,0.001
Pacific 578 69.4 32.6 to 99.5 ,0.001 621 66.5 25.9 to 97.2 ,0.001
Non-Ma¯ori/non-Pacific 11400 79.8 27.9 to 108.5 12473 76.3 26.0 to 105.1
Length of follow up
Ma¯ori 5654 3.1 0 to 14 ,0.001 5614 2.9 0 to 14 ,0.001
Pacific 3220 3.2 0 to 14 ,0.001 2510 2.7 0 to 14 ,0.001
Non-Ma¯ori/non-Pacific 28244 2.7 0 to 14 29605 2.6 0 to 14
*Comparing the Ma¯ori and Pacific groups with the non-Ma¯ori/non-Pacific group.
Table 2 Cause specific standardised mortality ratios among 37118 women hospitalised for diabetes, New Zealand, 1988 to
2001
Cause of death (ICD-9)
Maori (n = 5654) Pacific (n = 3220) Other (n = 28244)
Deaths SMR 95% CI Deaths SMR 95% CI Deaths SMR 95% CI
All deaths 2003 3.80 3.64, 3.97 578 2.41 2.21, 2.61 11400 2.98 2.93, 3.04
Infectious and parasitic diseases
(001–139)
15 3.17 1.77, 5.23 9 3.30 1.51, 6.26 55 3.42 2.57, 4.45
All cancers (150–208) 433 2.85 2.59, 3.14 119 1.81 1.50, 2.17 2032 2.59 2.48, 2.71
Endocrine, nutritional, and
metabolic (240–259, 270–279)
524 11.36 10.41, 12.37 166 5.81 4.96, 6.77 1797 18.49 17.65, 19.37
Mental disorders (290–319) 6 1.32 0.48, 2.88 6 1.65 0.60, 3.60 188 1.39 1.20, 1.61
Diseases of nervous system
(320–359)
11 3.58 1.79, 6.41 3 1.19 0.25, 3.49 114 1.38 1.14, 1.65
Diseases of circulatory system 665 3.03 2.81, 3.27 192 1.88 1.62, 2.17 5263 2.74 2.66, 2.81
Diseases the respiratory system
(460–519)
126 2.17 1.81, 2.59 26 1.50 0.98, 2.19 837 2.02 1.88, 2.16
Diseases of digestive system
(520–579)
52 4.39 3.28, 5.75 11 1.71 0.85, 3.06 371 2.83 2.55, 3.14
Diseases of genitourinary
system (580–629)
55 5.87 4.42, 7.64 11 2.86 1.43, 5.12 223 3.45 3.02, 3.94
Diseases of skin and
subcutaneous tissue (680–709)
6 3.71 1.36, 8.08 3 3.48 0.72, 10.18 21 2.05 1.27, 3.13
Diseases of musculoskeletal
system and connective
tissue (710–739)
9 4.57 2.09, 8.68 1 1.22 0.03, 6.76 72 1.95 1.53, 2.46
External causes (E800–E999) 17 1.96 1.14, 3.14 2 0.69 0.08, 2.50 178 2.19 1.88, 2.53
SMR, standardised mortality ratio; CI, confidence interval.
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cancers such as colorectal, breast, prostate, urinary, and
haematopoietic system.
Sex and ethnic specific SMRs for the major categories of
cause of death and also for specific subcategories of particular
interest are shown in table 2 (women) and table 3 (men).
SMRs, comparing the mortality experience among people
hospitalised for diabetes to the general population of the
same ethnicity, differed across the three ethnic groups. The
lowest excess mortality was in Pacific people, intermediate in
the non-Ma¯ori/non-Pacific group, and the highest SMRs in
Ma¯ori, both women and men.
Mortality patterns differed by cause, with the highest
SMRs seen for endocrine and metabolic disorders, reflecting
the use of a code for diabetes mellitus on the death
certificate. Mortality from cardiovascular disease was parti-
cularly high in the population with diabetes compared with
the general population, with differing patterns by ethnicity,
but similar SMRs in women and men. There was roughly
equal contribution to this raised SMR from ischaemic heart
and cerebrovascular disease (results not shown).
The significantly raised SMRs for diseases of the nervous,
respiratory and musculoskeletal systems, and diseases of the
skin and subcutaneous tissue and mental disorders show that
the mortality patterns that we see are comparatively non-
specific. The excess mortality from external causes differed by
ethnicity. Among Ma¯ori, the raised SMRs were equally
attributable to transport related accidents (ICD-9: 800 to
848) and other accidents (880 to 929), whereas in the non-
Ma¯ori/non-Pacific group, the greatest contribution to the
excess death from external causes was other accidents. SMRs
for suicide were significantly raised for non-Ma¯ori/non-
Pacific, but not for Ma¯ori people with diabetes. The few
deaths from external causes among Pacific people (n=12)
precluded further interpretation of these results.
Excess mortality from cancer was evident in each ethnic
group and both sexes. In addition to raised SMRs for
pancreatic cancer, mortality was high for both smoking
related and non-smoking related cancers. Table 4 shows
further details of these associations. Unlike for cardiovascular
diseases, the excess mortality seemed to be similar across the
ethnic groups for many of the sites at which the SMRs were
raised.
DISCUSSION
The findings from our study are in agreement with a number
of previous studies, showing increased risks of all cause and
cardiovascular disease mortality in a cohort of patients
discharged from hospital with diabetes. Because of the large
size of the cohort, we were also able to explore cause specific
mortality, which was found to be raised in comparison with
the general population for most causes of death. Importantly,
we found that the pattern of excess mortality, although
broadly similar across ethnic groups, was substantially higher
in Ma¯ori and lower in Pacific people compared with non-
Ma¯ori/non-Pacific people for cardiovascular disease, the
single greatest contributor to the excess mortality in patients
with diabetes.
The study was based only a cohort of diabetes patients who
were hospitalised, thus including those patients with more
severe disease than a community based sample.
This raises the potential for reverse causality, as we are
unable to determine either the temporality of the onset of
diabetes and other comorbidities that could underlie the
cause of death. This issue may be particularly important for
the results for cancer mortality, as cancer treatments could
lead to diabetes. Nor could we exclude the possibility of
detection bias, as patients could have been admitted to
hospital for a reason related to their cause of death, and had
diabetes diagnosed for the first time in hospital, thus creating
a spurious association between diabetes and mortality.
Because of the completeness of the data in the NMDS, we
restricted our analyses to discharges from public hospitals, at
which access to care is free. We estimate that about 2% of all
diagnoses of diabetes may have been omitted from our
analyses through the omission of private hospital diagnoses.
It is unlikely that this will have had a large impact on our
results. We chose to use a cut off of age 25 years at hospital
discharge to define adult onset disease. This is likely to be
reasonably reliable in the later years of the data, because
someone who was discharged from hospital for the first time
and had not been discharged in the previous 10 years is likely
to have been comparatively recently diagnosed. However, for
the earlier years of the data, we are likely to have included a
proportion of patients with type 1 diabetes, if they had been
incorrectly coded as type 2 instead of type 1. This could
Table 3 Cause specific standardised mortality ratios among 37729 men hospitalised for diabetes, New Zealand, 1988 to
2001
Cause of death (ICD-9)
Maori (n = 5614) Pacific (n = 2510) Other (n = 29605)
Deaths SMR 95% CI Deaths SMR 95% CI Deaths SMR 95% CI
All deaths 2220 3.44 3.30, 3.58 621 2.23 2.06, 2.41 12473 2.99 2.93, 3.04
Infectious and parasitic
diseases (001–139)
22 3.76 2.36, 5.70 14 4.18 2.28, 7.01 65 3.48 2.69, 4.43
All cancers (150–208) 414 2.26 2.05, 2.49 138 1.75 1.47, 2.07 2628 2.31 2.22, 2.40
Endocrine, nutritional and
metabolic (240–259, 270–279)
585 10.42 9.59, 11.30 148 6.21 5.25, 7.30 1864 17.45 16.66, 18.26
Mental disorders (290–319) 6 1.32 0.48, 2.87 1 0.35 0.01, 1.95 144 1.82 1.54, 2.15
Diseases of nervous system
(320–359)
11 2.80 1.40, 5.01 4 1.54 0.42, 3.94 134 1.63 1.37, 1.93
Diseases of circulatory system 860 3.08 2.87, 3.29 225 1.99 1.73, 2.26 5615 2.94 2.86, 3.02
Diseases the respiratory system
(460–519)
113 1.91 1.57, 2.29 39 1.32 0.94, 1.80 987 1.98 1.85, 2.10
Diseases of digestive system
(520–579)
55 3.78 2.85, 4.92 14 1.45 0.79, 2.43 357 3.29 2.96, 3.65
Diseases of genitourinary
system (580–629)
40 3.51 2.51, 4.78 6 1.14 0.42, 2.49 215 2.99 2.61, 3.42
Diseases of skin and
subcutaneous tissue (680–709)
7 6.56 2.63, 13.52 2 2.56 0.31, 9.24 25 4.22 2.73, 6.24
Diseases of musculoskeletal
system and connective tissue
(710–739)
5 2.58 0.84, 6.03 0 – 49 2.75 2.04, 3.64
External causes (E800–E999) 38 1.92 1.36, 2.63 10 2.07 0.99, 3.81 185 1.88 1.62, 2.17
SMR, standardised mortality ratio; CI, confidence interval.
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explain the comparatively high all cause SMR that we report
in comparison with other studies, as SMRs tend to be higher
for type 1 than type 2 diabetes.4
Although the recording of diabetes on death certificates of
people with diabetes is notoriously low, both in New
Zealand14 and internationally, this will not affect the results
that we present for cardiovascular disease or cancer, because
there is no reason to think that these causes of disease are
differentially underreported in patients with and without
diabetes. Similarly, although the high prevalence of undiag-
nosed patients with suspected diabetes in New Zealand is
high,15 this should not affect the results from the sample on
which the analysis is based.
Previous studies of mortality among diabetic patients have
found similar results to ours, with excess mortality from all
causes, cardiovascular disease, and renal disease evident in
most reports.1 6–8 The evidence for the presence of a positive
association between diabetes and cancer mortality is less
consistent. Many studies have shown that patients with
diabetes are at a higher risk of liver8 and pancreatic
cancer,16 17 with SMRs of over threefold commonly reported.
There is less consistency in the reported associations between
cancer mortality in populations with type 2 diabetes
compared with the general population. Several of the cohort
studies that have failed to find an association between
diabetes and all cancer mortality include a very small number
of cases, such as a follow up of the NHANES-1 survey (486
deaths among patients with diabetes)18 the Whitehall cohort
of men (188 deaths)17 compared with over 2500 in our study.
A Swedish study of similar design to ours reported an SMR of
1.46 (95% CI: 1.40, 1.52) in their group of hospitalised
patients who had ‘‘probably NIDDM’’. A SMR of similar
magnitude was found in the probable IDDM group.
Associations between diabetes and cause specific mortality
may be evident because of shared common risk factors (for
example, smoking) or an influence of lack of glycaemic
Table 4 Cancer site specific standardised mortality ratios among 74847 people hospitalised for diabetes, New Zealand,
1988 to 2001
Cause of death ICD-9
Maori (n = 11268) Pacific (n = 5730) Other (n = 57849)
Deaths SMR 95% CI Deaths SMR 95% CI Deaths SMR 95% CI
Lip, oro-pharynx
women 3 3.46 0.71, 10.13 0 – 20 2.32 1.41, 3.58
men 2 0.57 0.07, 2.06 2 0.88 0.11, 3.17 33 1.91 1.32, 2.69
Oesophagus
women 4 2.13 0.58, 5.45 1 5.66 0.14, 31.44 29 1.48 0.99, 2.13
men 4 0.63 0.17, 1.61 3 3.64 0.75, 10.64 71 1.97 1.54, 2.48
Stomach
women 25 3.10 2.01, 4.58 10 2.38 1.14, 4.38 54 1.88 1.42, 2.46
men 39 2.91 2.07, 3.98 4 0.59 0.16, 1.52 108 2.19 1.79, 2.64
Colon
women 5 1.10 0.36, 2.57 3 1.45 0.30, 4.24 195 1.89 1.63, 2.17
men 17 2.27 1.32, 3.63 3 1.01 0.21, 2.96 233 2.21 1.94, 2.52
Rectum
women 7 1.60 0.64, 3.30 5 2.75 0.89, 6.41 89 2.24 1.80, 2.76
men 15 2.09 1.17, 3.44 7 2.67 1.07, 5.51 132 2.08 1.74, 2.47
Liver
women 12 5.78 2.98, 10.09 3 1.21 0.25, 3.54 36 4.29 3.01, 5.94
men 33 3.55 2.44, 4.98 9 1.80 0.82, 3.41 79 5.45 4.31, 6.79
Pancreas
women 32 4.88 3.34, 6.89 4 2.29 0.62, 5.86 173 4.60 3.94, 5.34
men 25 3.40 2.20, 5.02 6 2.17 0.79, 4.72 197 4.75 4.11, 5.46
Lung
women 150 2.70 2.29, 3.17 18 1.62 0.96, 2.56 273 2.69 2.38, 3.03
men 138 2.09 1.76, 2.47 38 1.64 1.16, 2.25 552 2.26 2.08, 2.46
Melanoma
women 2 2.43 0.29, 8.77 1 7.46 0.19, 41.46 39 2.24 1.59, 3.06
men 0 – 0 – 66 2.01 1.56, 2.56
Breast
women 41 1.98 1.42, 2.69 14 1.28 0.70, 2.14 298 2.60 2.31, 2.91
Prostate
men 40 1.91 1.36, 2.60 21 1.84 1.14, 2.82 361 1.79 1.61, 1.99
Bladder
women 3 1.99 0.41, 5.82 0 – 40 2.34 1.67, 3.19
men 3 1.64 0.34, 4.80 3 2.54 0.52, 7.44 100 2.51 2.04, 3.05
Kidney
women 6 4.15 1.52, 9.03 0 – 45 3.17 2.31, 4.24
men 14 4.14 2.26, 6.94 3 2.56 0.53, 7.48 65 2.67 2.06, 3.40
Brain
women 3 2.27 0.47, 6.64 2 1.31 0.16, 4.74 50 3.54 2.63, 4.66
men 4 2.04 0.56, 5.23 2 2.51 0.30, 9.05 62 2.93 2.25, 3.76
Non-Hodgkin’s lymphoma
women 10 2.59 1.24, 4.76 8 2.63 1.13, 5.17 85 2.74 2.19, 3.38
men 9 2.24 1.02, 4.26 7 2.30 0.92, 4.73 112 2.86 2.35, 3.44
Multiple myeloma
women 7 2.92 1.17, 6.02 5 2.73 0.88, 6.37 38 2.35 1.66, 3.23
men 17 4.20 2.44, 6.72 3 1.25 0.26, 3.67 42 2.00 1.44, 2.70
Lymphoid leukaemia
women 4 4.03 1.10, 10.31 0 – 24 2.87 1.84, 4.27
men 7 4.91 1.97, 10.12 0 – 34 2.57 1.78, 2.59
Myeloid leukaemia
women 5 2.38 0.77, 5.57 2 1.38 0.17, 4.99 44 3.28 2.38, 4.40
men 3 1.40 0.29, 4.10 3 1.85 0.38, 5.41 49 2.26 1.68, 2.99
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control on vascular or other tissues. It is probable that
associations between smoking related cancers and diabetes
may be attributable to the common cause of smoking in these
cancers and the development of diabetes.19 20 However, such
obvious confounding is less clear for non-smoking related
cancers.
There is accumulating evidence that colorectal cancer risk
is higher in patients with diabetes, and in particular this
increased risk may be related to glycaemic control.21 Such
findings shed important light on the role of the insulin/
insulin-like growth factor (IGF) axis in the development of or
survival from these cancers. One of the symptoms of insulin
resistance is high levels of circulating insulin, which are
related to increased bioactivity of IGF-I, as well as to its
bioavailability through the association with IGF binding
proteins.22 23 Hyperinsulinaemia has been related to several
hormone responsive cancers,24 particularly of the colorectum,
endometrium, and breast.25 Several previous studies
(reviewed in Rodriguez et al26) have shown lower risks of
prostate cancer in patients with diabetes compared with the
general population. We have found moderately raised SMRs
for prostate cancer, consistent with the suggestion that high
insulin levels present during insulin resistance and the early
phase of diabetes are associated with prostate cancer risk. It
has been proposed that the relation between diabetes and
prostate cancer is modified by duration of diabetes, with
higher risks of prostate cancer in the early years after a
diabetes diagnosis reducing to lower risks in later years.26 27
Given the decades during which prostate cancer develops,
these data suggest that raised insulin levels may act as a
promoter of prostate cancer, rather than having a carcino-
genic effect in itself.
Some studies have reported sex differences in the mortality
experiences of diabetic patients. However, most larger
studies, such as NHANES18 and the Swedish linkage study4
found no evidence to suggest sex differences in mortality
among diabetics. In this study, most off the site specific
SMRs are similar in women and men. An important finding
in this study was the high SMR among Ma¯ori for
cardiovascular disease compared with the other ethnic
groups. This is likely to reflect poorer glycaemic control and
hence more severe macro-vascular complications among
Ma¯ori, who are known to be medically underserved in New
Zealand according to their need.28
The results for Pacific people in these data are intriguing,
with SMRs, particularly those for cancer and cardiovascular
disease, consistently lower that the Ma¯ori or non-Ma¯ori/non-
Pacific group. Through the inclusion only of New Zealand
residents, we have minimised the risk to including patients
from the Pacific who come to New Zealand for treatment.
Although we cannot rule out the possibility of selective
emigration of sick people, this is not thought to account for
the mortality patterns seen in Pacific people in New Zealand
(C Wright, personal communication, 2004). Although lower
mortality among Hispanic people in America has been
described, this ‘‘Hispanic-paradox’’ has not been replicated
in studies of diabetes, with Mexican Americans born in the
USA experiencing higher mortality rates than non-Hispanic
white people.29
In summary, we have reported high SMRs for several
causes of death in a cohort of patients admitted to hospital
for diabetes. The findings with respect to cancer add to our
understanding of the aetiology of non-smoking related
cancers. The pattern of excess mortality by ethnicity should
be further investigated, as this may be amenable to
intervention to improve outcomes for Ma¯ori.
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Sir John Pringle’s Observations on the Diseases of the Army—an early scientific account of
epidemiology and the prevention of cross infection
B
orn in 1707, Pringle studied medicine at
Leiden and Paris before practising in
Edinburgh. In 1744 he became physi-
cian general to the British army and he was
present at the battle of Culloden. In 1752 the
first of the many editions of Pringle’s Diseases
of the Army was published. In the volume
Pringle identified hospitals as a major cause
of sickness and began to think in terms of
septic and antiseptic. Pringle felt that fevers,
dysentery, and jail fever were the three most
prevalent and fatal diseases affecting armies
and although he was wrong about the way
they were transmitted (he blamed putrid air)
his recommendations for prevention helped
to control epidemics. After his retiral from
the army Pringle started a successful London
practice. He was a president of the Royal
Society and physician-in-ordinary to the
king. Sir John died in 1782.
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